We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




NIST Standard Will Help Diagnosis, Treatment of Cytomegalovirus

By LabMedica International staff writers
Posted on 23 Jan 2012
A new clinical Standard Reference Material (SRM) will help healthcare professionals more accurately diagnose and treat Cytomegalovirus (CMV), a common pathogen that is particularly dangerous for infants and persons with weakened immune systems.

If a CMV infection becomes dangerous, antiviral agents can be used to moderate the impact. More...
Many of these compounds are toxic, so the physician must know the severity of the infection--a measure known as viral load (number of virus copies per microliter of blood)--to prescribe the optimal dosage and duration of treatment.

The current means of measuring viral load is to use polymerase chain reaction (PCR) to amplify a region of the CMV gene and then use a calibration curve to estimate the number of virus particles in the original sample. Accuracy of these measurements can vary greatly from one test facility to another, as there are many different PCR protocols used to determine viral load, including commercial and "in-house" laboratory assays.

The new [US] National Institute of Standards and Technology (NIST; Gaithersburg, MD, USA) reference, SRM 2366, provides a standardized CMV DNA. Consistency of the viral DNA in the standard was ensured by manufacturing it in Escherichia coli bacteria. These E. coli cells each contain a copy of the CMV genome in a "DNA construct"--an artificially constructed segment of nucleic acid that codes for a specific product, in this case, CMV DNA. The DNA copies made by this E. coli cell culture can then be purified and quantified using digital polymerase chain reaction (PCR).

SRM 2366 consists of three solutions, each with a specific concentration of CMV DNA copies per microliter: 420, 1,702, and 19,641. These are designed to qualify prepared calibration samples. They also can be used as quality control samples for diagnostic equipment. For added traceability, the SRM certificate of analysis includes the genetic sequences of the nine CMV genome regions copied for the standard.

CMV is found in 50% to 80 % of the population. CMV generally remains latent in an infected person unless certain conditions trigger its activation. CMV poses a significant health risk to people who are immunocompromised and babies who receive the virus from their mothers before birth. Congenital CMV infections cause more long-term problems and childhood deaths than many other prenatal disorders including fetal alcohol syndrome, Down syndrome, and neural tube defects such as spina bifida.

Related Links:

National Institute of Standards and Technology




New
Gold Member
Collection and Transport System
PurSafe Plus®
Collection and Transport System
PurSafe Plus®
New
Gel Cards
DG Gel Cards
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The nanotechnology-based liquid biopsy test could identify cancer at its early stages (Photo courtesy of 123RF)

2-Hour Cancer Blood Test to Transform Tumor Detection

Glioblastoma and other aggressive cancers remain difficult to control largely because tumors can recur after treatment. Current diagnostic methods, such as invasive biopsies or expensive liquid biopsies,... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.